Showing 1381-1390 of 3884 results for "".
The Best Skincare Products for Eczema, According to Your Peers
https://practicaldermatology.com/topics/atopic-dermatitis/the-best-skincare-products-for-eczema-according-to-your-peers/23747/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-36/23740/Applying White Glove Service in the Practice
https://practicaldermatology.com/topics/practice-management/applying-white-glove-service-in-the-practice/23643/Help set your practice apart with these tips for providing unparalleled customer service to your patients.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyOlympics Lesson: Prioritize Mental Health Over Our Own Gold Medals
https://practicaldermatology.com/topics/practice-management/olympics-lesson-prioritize-mental-health-over-our-own-gold-medals/23600/Seeking help is an act of bravery not a show of weakness.Ancillary Services and Alternative Revenue Streams for Dermatologists
https://practicaldermatology.com/topics/practice-management/ancillary-services-and-alternative-revenue-streams-for-dermatologists/23535/Dermatologists have many opportunities to use their skills beyond patient care.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesPulse’s CellFX for Dermatologic Applications
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pulses-cellfx-for-dermatologic-applications/23464/A novel technology targets cells to treat warts, sebaceuous hyperplasia, and more.Reclaiming “Quality” in Dermatology
https://practicaldermatology.com/topics/practice-management/reclaiming-quality-in-dermatology/23432/Dermatologists know quality care when they see it. It’s time to take an active role in defining meaningful quality measures.2020 In Review
https://practicaldermatology.com/topics/skin-cancer-photoprotection/2020-in-review/23402/Top trends and developments from the year